What patient factors do you consider when selecting between a small interfering RNA, like inclisiran, and PCSK9 inhibitors in patients with recent acute coronary syndrome?

Insurance coverage and out-of-pocket costs usually drive my choice. It is fairly easy to get approval for evolocumab for most of my patients. I have had a hard time getting approval for inclisiran with the exception of those with traditional Medicare + supplemental medication coverage. I usually sta...

Overall, I see both the inclisiran (siRNA) and evolocumab/ alirocumab (monoclonal antibodies) as PCSK9 modulators (inhibitors). As you know, we are awaiting the results from the outcomes study for inclisiran, while on the other hand, both alirocumab and evolocumab have shown a reduction in major adv...